At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7 enrolled
Drug / intervention
Hydrocortisone sodium acetatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia
In Brief
A clinical study evaluating Hydrocortisone sodium acetate for Adrenal Hyperplasia, Congenital. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The purpose of this study is to develop a more physiological approach to the management of children and adolescents with salt wasting Congenital Adrenal Hyperplasia. We will administer the glucocorticosteroid via insulin infusion pump to see whether this treatment will improve the serum hormone concentrations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdrenal Hyperplasia, Congenital
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedSep 2007
Primary CompletionSep 2008
TodayJul 2026
First PostedSep 14, 2007
Enrollment StartJan 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.8 years ago
Interventions
Hydrocortisone sodium acetatedrug
Subcutaneous administration of medication via insulin pump